MedTrace Logo

Application Based Addiction Treatment Adherence Trial

NCT04680741 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2025-02-25

No results posted yet for this study

Summary

The purpose of this study is to test a smart phone based application (the App) that will allow patients to record their attendance at 12-step meetings. The smart phone application is an investigational (experimental) application that works by allowing patients to check in to meetings and tracks their location. This application uses features available in smartphone technology and will be tested on a small scale in order to ascertain interest and benefit in a controlled manner. The initial phase of this process is a test of concept, which poses the question of whether individuals in an office-based addiction treatment program will utilize the application to check in and out of meetings, and answer a brief questionnaire delivered via the app at the end of a meeting. In this phase, investigators will set the standard recommendation as attendance at a minimum of three meetings per week.

Conditions

  • Opiate Use Disorder

Interventions

BEHAVIORAL

Addiction Pilot App behavior tracking

a smartphone-based application (app) which is designed to monitor attendance at twelve-step facilitation meetings.

Sponsors & Collaborators

  • Open Health Network

    collaborator UNKNOWN

  • The Cleveland Clinic

    lead OTHER

Principal Investigators

  • Robert Bales, MD · The Cleveland Clinic

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-17
Primary Completion
2021-06-25
Completion
2023-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04680741 on ClinicalTrials.gov